Document is current

Article History

Received: 4 February 2025

Accepted: 15 April 2025

First Online: 30 May 2025

Declarations

:

: Joseph F. Merola is a consultant and/or investigator for AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Janssen, Leo Pharma, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Philip J. Mease has received research grants and consulting and/or speaker fees from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Century, CorEvitas, Cullinan, Janssen, Lilly, MoonLake Immunotherapeutics, Novartis, Pfizer, Sana, and UCB. April W. Armstrong is an investigator, scientific advisor, and/or speaker for AbbVie, Almirall, Arcutis, Aslan Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI Health, Incyte, Janssen, Leo Pharma, Lilly, Mindera Health, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Vibeke Strand is a consultant for AbbVie, Alpine Immune Sciences, Alumis, Amgen, Aria, AstraZeneca, Atom Bioscience, Bayer, Bioventus, Blackrock, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Endo, Equillium, Ermium, Fortress Biotech, Genentech/Roche, Gilead, GSK, Horizon, Inmedix, Janssen, Kiniksa, Lilly, Merck, MiMedx, Novartis, Omeros, Pfizer, Priovant, Regeneron, R-Pharm, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Sorrento, Spherix, and Tonix. Thomas Lehman, Stefan Varga, Brandon Becker, Yichen Zhong, and Matthew J. Colombo are employees of and shareholders in Bristol Myers Squibb. Jiyoon C. Choi is an employee of Bristol Myers Squibb and is a shareholder in Bristol Myers Squibb and Johnson and Johnson. Diamant Thaçi is an investigator, consultant, lecturer, and/or serves on scientific advisory boards for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Janssen-Cilag, Leo Pharma, Lilly, Novartis, Pfizer, Regeneron, Roche-Posay, Sanofi, Target RWE, and UCB. Androniki Bili was an employee of Bristol Myers Squibb at the time of this study. Alice B. Gottlieb has received research and/or educational grants (all paid to Mount Sinai School of Medicine) from Bristol Myers Squibb, Highlights Therapeutics, Janssen, and UCB; has served as a remunerated advisory board member and/or consultant for Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Highlights Therapeutics, Janssen, Lilly, Novartis, Sanofi, UCB, and XBiotech (stock options).

: The POETYK PSO-1 and PSO-2 trials were conducted in accordance with Good Clinical Practice, as defined by the International Council for Harmonization and the Declaration of Helsinki, with independent IRB approval obtained at each study site. All patients in POETYK PSO-1 and PSO-2 also provided written informed consent before trial participation. Permission to use the PASE questionnaire was obtained under the Creative Commons Attribution License.